In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets

Preclinical molecular models are useful that mimic a patient´s response to targeted therapy. Here, the authors establish an in vivo inducible RNAi-mediated gene silencing system in patient-derived xenograft models of acute leukemia to identify individual vulnerabilities and therapeutic targets.

Guardado en:

Detalles Bibliográficos
Autores principales:	Michela Carlet, Kerstin Völse, Jenny Vergalli, Martin Becker, Tobias Herold, Anja Arner, Daniela Senft, Vindi Jurinovic, Wen-Hsin Liu, Yuqiao Gao, Veronika Dill, Boris Fehse, Claudia D. Baldus, Lorenz Bastian, Lennart Lenk, Denis M. Schewe, Johannes W. Bagnoli, Binje Vick, Jan Philipp Schmid, Alexander Wilhelm, Rolf Marschalek, Philipp J. Jost, Cornelius Miething, Kristoffer Riecken, Marc Schmidt-Supprian, Vera Binder, Irmela Jeremias
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/6e797a213a574904a9cff02ded829844
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6e797a213a574904a9cff02ded829844
record_format	dspace
spelling	oai:doaj.org-article:6e797a213a574904a9cff02ded8298442021-12-02T19:17:06ZIn vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets10.1038/s41467-021-25963-z2041-1723https://doaj.org/article/6e797a213a574904a9cff02ded8298442021-09-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-25963-zhttps://doaj.org/toc/2041-1723Preclinical molecular models are useful that mimic a patient´s response to targeted therapy. Here, the authors establish an in vivo inducible RNAi-mediated gene silencing system in patient-derived xenograft models of acute leukemia to identify individual vulnerabilities and therapeutic targets.Michela CarletKerstin VölseJenny VergalliMartin BeckerTobias HeroldAnja ArnerDaniela SenftVindi JurinovicWen-Hsin LiuYuqiao GaoVeronika DillBoris FehseClaudia D. BaldusLorenz BastianLennart LenkDenis M. ScheweJohannes W. BagnoliBinje VickJan Philipp SchmidAlexander WilhelmRolf MarschalekPhilipp J. JostCornelius MiethingKristoffer RieckenMarc Schmidt-SupprianVera BinderIrmela JeremiasNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Michela Carlet Kerstin Völse Jenny Vergalli Martin Becker Tobias Herold Anja Arner Daniela Senft Vindi Jurinovic Wen-Hsin Liu Yuqiao Gao Veronika Dill Boris Fehse Claudia D. Baldus Lorenz Bastian Lennart Lenk Denis M. Schewe Johannes W. Bagnoli Binje Vick Jan Philipp Schmid Alexander Wilhelm Rolf Marschalek Philipp J. Jost Cornelius Miething Kristoffer Riecken Marc Schmidt-Supprian Vera Binder Irmela Jeremias In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets
description	Preclinical molecular models are useful that mimic a patient´s response to targeted therapy. Here, the authors establish an in vivo inducible RNAi-mediated gene silencing system in patient-derived xenograft models of acute leukemia to identify individual vulnerabilities and therapeutic targets.
format	article
author	Michela Carlet Kerstin Völse Jenny Vergalli Martin Becker Tobias Herold Anja Arner Daniela Senft Vindi Jurinovic Wen-Hsin Liu Yuqiao Gao Veronika Dill Boris Fehse Claudia D. Baldus Lorenz Bastian Lennart Lenk Denis M. Schewe Johannes W. Bagnoli Binje Vick Jan Philipp Schmid Alexander Wilhelm Rolf Marschalek Philipp J. Jost Cornelius Miething Kristoffer Riecken Marc Schmidt-Supprian Vera Binder Irmela Jeremias
author_facet	Michela Carlet Kerstin Völse Jenny Vergalli Martin Becker Tobias Herold Anja Arner Daniela Senft Vindi Jurinovic Wen-Hsin Liu Yuqiao Gao Veronika Dill Boris Fehse Claudia D. Baldus Lorenz Bastian Lennart Lenk Denis M. Schewe Johannes W. Bagnoli Binje Vick Jan Philipp Schmid Alexander Wilhelm Rolf Marschalek Philipp J. Jost Cornelius Miething Kristoffer Riecken Marc Schmidt-Supprian Vera Binder Irmela Jeremias
author_sort	Michela Carlet
title	In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets
title_short	In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets
title_full	In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets
title_fullStr	In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets
title_full_unstemmed	In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets
title_sort	in vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6e797a213a574904a9cff02ded829844
work_keys_str_mv	AT michelacarlet invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT kerstinvolse invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT jennyvergalli invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT martinbecker invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT tobiasherold invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT anjaarner invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT danielasenft invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT vindijurinovic invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT wenhsinliu invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT yuqiaogao invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT veronikadill invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT borisfehse invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT claudiadbaldus invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT lorenzbastian invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT lennartlenk invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT denismschewe invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT johanneswbagnoli invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT binjevick invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT janphilippschmid invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT alexanderwilhelm invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT rolfmarschalek invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT philippjjost invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT corneliusmiething invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT kristofferriecken invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT marcschmidtsupprian invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT verabinder invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets AT irmelajeremias invivoinduciblereversegeneticsinpatientstumorstoidentifyindividualtherapeutictargets
_version_	1718376917379317760

In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets

Ejemplares similares